Disease relevance of Thrombectomy

• Central venous septic thrombosis managed by superior vena cava Greenfield filter and venous thrombectomy: a case report [1].
• The treatment strategy includes catheter-directed thrombolysis with intrathrombus infusion of the plasminogen activator or operative thrombectomy or venous bypass with a permanent 4 mm arteriovenous fistula (AVF) [2].
• The inferior vena cava filter was inserted before venous thrombectomy to prevent pulmonary embolism from dislodged clots during the latter procedure [3].
• METHODS: From January 1993 to June 2001, in 53 patients with extended DVT, unsuccessful venous thrombectomy (recanalization, <50%) was followed by RHFP with 0.5 mg/kg of body weight of recombinant tissue plasminogen activator [4].
• Bilateral renal vein and inferior vena cava thrombosis with nephrotic syndrome treated by thrombectomy: case report with 3-year followup [5].

High impact information on Thrombectomy

• This report summarizes our experience with caval thrombectomy and reconstruction that allowed complete removal of all gross tumor in seven patients with malignant occlusion of the retrohepatic inferior vena cava [6].
• Anticoagulation therapy with heparin or thrombectomy are treatment options [7].
• In organ chamber studies, endothelium-dependent relaxations to calcium ionophore, but not adenosine diphosphate, were inhibited by an antagonist of nitric oxide production after thrombectomy (P <.05, thrombectomy vs sham- and thrombolysis-treated veins) [8].
• The sixth patient required two thrombectomies and warfarin [9].
• Balloon catheter thrombectomy significantly reduced endothelium-dependent relaxations compared with all other groups in response to acetylcholine, bradykinin, and thrombin (p < 0.001) [10].

Chemical compound and disease context of Thrombectomy

• The treatment has two aims: first, to restore arterial patency by clot removal by thrombectomy, bypass or thrombolysis, and second, to avoid new thrombosis formation by substitutive anticoagulation treatment: danaparoid may have cross-reaction with heparin, or lepirudin has anaphylactic risks and needs biological follow-up [11].
• These factors were gender, diabetes, hypertension, aspirin, warfarin, ischaemic heart disease, run-off, graft type, early thrombectomy, level of anastomoses and indication for surgery [12].
• The aim of this paper was to evaluate the influence of Clopidogrel on the incidence of early secondary thrombosis complications after restoring patency of fistula with surgical thrombectomy [13].
• Heparin, heparin plus ASA and dipyridamole, and arteriovenous fistula as adjuvant methods to prevent rethrombosis after venous thrombectomy. Experimental study in rabbits [14].

Biological context of Thrombectomy

• A novel approach was used to prevent microvascular obstruction and reperfusion injury, with a distal protection system, a thrombectomy device, and administration of intracoronary adenosine prior to restoration of flow, so that initial reperfusion was done with maximal microvascular vasodilatation [15].

Anatomical context of Thrombectomy

• Left ventricular thrombectomy in a cocaine user with normal coronary arteries [16].
• Surgical repair consisted of thrombectomy of all the involved vessels and patch repair of superior vena cava and innominate vein [17].
• After thrombectomy, 10 patients received adjunctive reteplase thrombolysis for treatment of residual thrombus, and 12 received inferior vena cava (IVC) filters [18].
• More importantly, two patients receiving protamine, thrombosed the operated internal carotid artery (ICA) postoperatively and died despite urgent thrombectomy [19].
• We report a technique for tumor thrombectomy of the inferior vena cava for renal cell carcinoma extending into the right atrium that abrogates the need for thoracotomy or sternotomy [20].

Associations of Thrombectomy with chemical compounds

• Only 2 (17%) graft limbs had no luminal defects after thrombectomy [21].
• Heparin (10 units/min) and nitroglycerin (50 micrograms/min) were the agents infused most frequently, for a mean duration of 52 hours after thrombectomy [22].
• To evaluate the clinical effectiveness of rheolytic thrombectomy in a nonselected population in the glycoprotein IIb/IIIa blockade era, we reviewed clinical, angiographic, and procedural data on 119 patients who underwent 126 consecutive coronary AngioJet procedures (29% in SVGs, and 71% in native coronary arteries) from July 1998 to August 2000 [23].
• She was treated aggressively with pentobarbital coma, angiography, and thrombectomy and recovered with minimal deficit [24].
• In 24 patients the method of surgical thrombectomy proved to be effective and they received a preventive dose of Clopidogrel [75 mg per 24h] for 28 days [13].

Gene context of Thrombectomy

• PURPOSE: To determine if the lyse and wait (L&W) technique with a 4-mg dose of alteplase (tissue plasminogen activator; tPA) is a safe and effective method of declotting dialysis grafts as compared to use of the Arrow-Trerotola Percutaneous Thrombectomy Device (PTD) or the L&W technique with use of urokinase (UK) [25].
• Current status of percutaneous mechanical thrombectomy. Part III. Present and future applications [26].
• The use of mechanical thrombectomy devices in the management of acute peripheral arterial occlusive disease [27].
• Arterialized flow was re-established by hydrodynamic thrombectomy and PTA in 43 of 51 cases (84%) [28].
• There were 1.188 thrombectomies and 0.222 mechanical problems per 1,000 patient-days prior to the initiation of EPO treatment [29].

Analytical, diagnostic and therapeutic context of Thrombectomy

• Angioscopy revealed luminal defects in 10 (83%) graft limbs after blind retrograde thrombectomy [21].
• Secondary patency, maintained by thrombectomy (n = 7), revision (n = 3), and conversion to warfarin sodium (Coumadin) therapy (n = 6) was 100% at 2 years, and limb salvage was achieved for all surviving patients [30].
• A combination of AngioJet rheolytic catheter thrombectomy, balloon angioplasty, and continuous direct superior sagittal sinus recombinant tissue plasminogen activator infusion led to venous recanalization with a successful clinical outcome, without worsening of the preexisting intracranial hemorrhages [31].
• Treatment strategies included discontinuation of heparin in all patients and intravenous infusion of dextran, followed by arterial thrombectomy in four patients, urokinase therapy in two patients for arterial complications, and insertion of Greenfield filters in six patients [32].
• There is renewed interest in the use of operative thrombectomy in the management of acute DVT using the adjuncts of heparin infusion through an indwelling catheter and pneumatic segmental compression of the leg [33].

References